Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs

Transl Cancer Res. 2023 Mar 31;12(3):688-691. doi: 10.21037/tcr-22-2841. Epub 2023 Feb 27.
No abstract available

Keywords: Checkpoint inhibitors; Response Evaluation Criteria in Solid Tumors (RECIST); abscopal response; oligoprogression; radiotherapy.

Publication types

  • Editorial
  • Comment